Peter J. Fromen
Chief Executive Officer chez Biomodal Ltd.
Profil
Peter J.
Fromen holds the position of Chief Executive Officer & Director at Cambridge Epigenetix Ltd.
and Chief Executive Officer & Director at Cambridge Epigenetix Ltd.
In the past he occupied the position of Senior Director-Investor Relations at Illumina, Inc. and Chief Commercial Officer at Pacific Biosciences of California, Inc.
Peter J.
Fromen received an undergraduate degree from Kenyon College and an MBA from W.P.
Carey School of Business.
Postes actifs de Peter J. Fromen
| Sociétés | Poste | Début |
|---|---|---|
Biomodal Ltd.
 Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 18/07/2022 |
Anciens postes connus de Peter J. Fromen
| Sociétés | Poste | Fin |
|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Corporate Officer/Principal | 20/05/2022 |
| ILLUMINA, INC. | Investor Relations Contact | - |
Formation de Peter J. Fromen
| Kenyon College | Undergraduate Degree |
| W.P. Carey School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ILLUMINA, INC. | Health Technology |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Biomodal Ltd.
Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
